Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer

1.

Sung, H., J. Ferlay, R.L. Siegel, et al.1, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021. 71(3): p. 209–249. https://doi.org/10.3322/caac.21660.

2.

Collignon, E., A. Canale, C. Al Wardi, et al.1, Immunity drives TET1 regulation in cancer through NF-κB. Science Advances. 4(6): p. eaap7309. https://doi.org/10.1126/sciadv.aap7309.

3.

Čelešnik, H. and U. Potočnik1, Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer. Cancers (Basel), 2022. 14(3): p. https://doi.org/10.3390/cancers14030591.

4.

Yersal, O. and S. Barutca1, Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol, 2014. 5(3): p. 412–24. https://doi.org/10.5306/wjco.v5.i3.412.

5.

Anderson, N.M. and M.C. Simon1, The tumor microenvironment. Current Biology, 2020. 30(16): p. R921-R925. https://doi.org/10.1016/j.cub.2020.06.081.

6.

Medler, J. and H. Wajant1, Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target. Expert Opinion on Therapeutic Targets, 2019. 23(4): p. 295–307. https://doi.org/10.1080/14728222.2019.1586886.

7.

Sheng, Y., F. Li, and Z. Qin1, TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors. Front Immunol, 2018. 9: p. 1170. https://doi.org/10.3389/fimmu.2018.01170.

8.

Fu Q, Shen Q, Tong J, et al. 1, Anti-Tumor Necrosis Factor Receptor 2 Antibody Combined With Anti-PD-L1 Therapy Exerts Robust Antitumor Effects in Breast Cancer. Front Cell Dev Biol. 2021;9: 720472. https://doi.org/10.3389/fcell.2021.720472.CrossRefPubMedPubMedCentral

9.

Yang Y, Islam MS, Hu Y, et al. 1, TNFR2: Role in Cancer Immunology and Immunotherapy. Immunotargets Ther. 2021;10:103–22. https://doi.org/10.2147/itt.S255224.CrossRefPubMedPubMedCentral

10.

Danenberg E, Bardwell H, Zanotelli VRT, et al. 1, Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nat Genet. 2022;54(5):660–9. https://doi.org/10.1038/s41588-022-01041-y.CrossRefPubMedPubMedCentral

11.

Li, J.J., J.Y. Tsang, and G.M. Tse1, Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment. Cancers (Basel), 2021. 13(16): p. https://doi.org/10.3390/cancers13164233.

12.

de Visser, K.E. and J.A. Joyce1, The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 2023. 41(3): p. 374–403. https://doi.org/10.1016/j.ccell.2023.02.016.

13.

Place, A.E., S. Jin Huh, and K. Polyak1, The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Research, 2011. 13(6): p. 227. https://doi.org/10.1186/bcr2912.

14.

Nallasamy P, Nimmakayala RK, Parte S, et al. 1, Tumor microenvironment enriches the stemness features: the architectural event of therapy resistance and metastasis. Mol Cancer. 2022;21(1):225. https://doi.org/10.1186/s12943-022-01682-x.CrossRefPubMedPubMedCentral

15.

Hill BS, Sarnella A, D’Avino G, et al. 1, Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. Semin Cancer Biol. 2020;60:202–13. https://doi.org/10.1016/j.semcancer.2019.07.028.CrossRefPubMed

16.

Terceiro, L.E.L., C.A. Edechi, N.M. Ikeogu, et al.1, The Breast Tumor Microenvironment: A Key Player in Metastatic Spread. Cancers (Basel), 2021. 13(19): p. https://doi.org/10.3390/cancers13194798.

17.

Li L, Ye R, Li Y, et al. 1, Targeting TNFR2 for cancer immunotherapy: recent advances and future directions. J Transl Med. 2024;22(1):812. https://doi.org/10.1186/s12967-024-05620-x.CrossRefPubMedPubMedCentral

18.

Beltinger CP, White PS, Maris JM, et al. 1, Physical Mapping and Genomic Structure of the HumanTNFR2Gene. Genomics. 1996;35(1):94–100. https://doi.org/10.1006/geno.1996.0327.CrossRefPubMed

19.

Martínez-Reza, I., L. Díaz, and R. García-Becerra1, Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer. J Biomed Sci, 2017. 24(1): p. 90. https://doi.org/10.1186/s12929-017-0398-9.

20.

Mukai, Y., T. Nakamura, M. Yoshikawa, et al.1, Solution of the Structure of the TNF-TNFR2 Complex. Science Signaling, 2010. 3(148): p. ra83-ra83. https://doi.org/10.1126/scisignal.2000954.

21.

Bodmer, J.-L., P. Schneider, and J. Tschopp1, The molecular architecture of the TNF superfamily. Trends in Biochemical Sciences, 2002. 27(1): p. 19–26. https://doi.org/10.1016/S0968-0004(01)01995-8.

22.

Chan FK, Chun HJ, Zheng L, et al. 1, A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000;288(5475):2351–4. https://doi.org/10.1126/science.288.5475.2351.CrossRefPubMed

23.

Vanamee, É.S. and D.L. Faustman1, Structural principles of tumor necrosis factor superfamily signaling. Science Signaling, 2018. 11(511): p. eaao4910. https://doi.org/10.1126/scisignal.aao4910.

24.

Siegmund, D. and H. Wajant1, TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond. Nature Reviews Rheumatology, 2023. 19(9): p. 576–591. https://doi.org/10.1038/s41584-023-01002-7.

25.

van Weverwijk, A. and K.E. de Visser1, Mechanisms driving the immunoregulatory function of cancer cells. Nature Reviews Cancer, 2023. 23(4): p. 193–215. https://doi.org/10.1038/s41568-022-00544-4.

26.

Black RA, Rauch CT, Kozlosky CJ, et al. 1, A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature. 1997;385(6618):729–33. https://doi.org/10.1038/385729a0.CrossRefPubMed

27.

Grech AP, Gardam S, Chan T, et al. 1, Tumor Necrosis Factor Receptor 2 (TNFR2) Signaling Is Negatively Regulated by a Novel, Carboxyl-terminal TNFR-associated Factor 2 (TRAF2)-binding Site*. J Biol Chem. 2005;280(36):31572–81. https://doi.org/10.1074/jbc.M504849200.CrossRefPubMed

28.

Faustman, D. and M. Davis1, TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov, 2010. 9(6): p. 482–93. https://doi.org/10.1038/nrd3030.

29.

Wajant, H., K. Pfizenmaier, and P. Scheurich1, Tumor necrosis factor signaling. Cell Death & Differentiation, 2003. 10(1): p. 45–65. https://doi.org/10.1038/sj.cdd.4401189.

30.

Vallabhapurapu S, Matsuzawa A, Zhang W, et al. 1, Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-κB signaling. Nat Immunol. 2008;9(12):1364–70. https://doi.org/10.1038/ni.1678.CrossRefPubMedPubMedCentral

31.

Rodríguez M, Cabal-Hierro L, Carcedo MT, et al. 1, NF-κB Signal Triggering and Termination by Tumor Necrosis Factor Receptor 2*. J Biol Chem. 2011;286(26):22814–24. https://doi.org/10.1074/jbc.M111.225631.CrossRefPubMedPubMedCentral

32.

Rauert H, Stühmer T, Bargou R, et al. 1, TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis. 2011;2(8):e194–e194. https://doi.org/10.1038/cddis.2011.78.CrossRefPubMedPubMedCentral

33.

Sakurai H, Miyoshi H, Toriumi W, et al. 1, Functional Interactions of Transforming Growth Factor β-activated Kinase 1 with IκB Kinases to Stimulate NF-κB Activation*. J Biol Chem. 1999;274(15):10641–8. https://doi.org/10.1074/jbc.274.15.10641.CrossRefPubMed

34.

Tada K, Okazaki T, Sakon S, et al. 1, Critical Roles of TRAF2 and TRAF5 in Tumor Necrosis Factor-induced NF-κB Activation and Protection from Cell Death*. J Biol Chem. 2001;276(39):36530–4. https://doi.org/10.1074/jbc.M104837200.CrossRefPubMed

35.

Borghi A, Haegman M, Fischer R, et al. 1, The E3 ubiquitin ligases HOIP and cIAP1 are recruited to the TNFR2 signaling complex and mediate TNFR2-induced canonical NF-κB signaling. Biochem Pharmacol. 2018;153:292–8. https://doi.org/10.1016/j.bcp.2018.01.039.CrossRefPubMed

36.

Fennell, L.M., C. Gomez Diaz, L. Deszcz, et al.1, Site-specific ubiquitination of the E3 ligase HOIP regulates apoptosis and immune signaling. Embo j, 2020. 39(24): p. e103303. https://doi.org/10.15252/embj.2019103303.

37.

Mohd Salim, N.H., A. Mussa, N. Ahmed, et al.1, The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment. Biomedicines, 2023. 11(1): p. https://doi.org/10.3390/biomedicines11010173.

38.

Nakshatri, H. and R.J. Goulet1, NF-κB and breast cancer. Current Problems in Cancer, 2002. 26(5): p. 282–309. https://doi.org/10.1067/mcn.2002.129977.

39.

Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. 1, CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature. 2003;424(6950):793–6. https://doi.org/10.1038/nature01803.CrossRefPubMed

40.

Reiley W, Zhang M, Wu X, et al. 1, Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol. 2005;25(10):3886–95. https://doi.org/10.1128/mcb.25.10.3886-3895.2005.CrossRefPubMedPubMedCentral

41.

Al-Lamki, R.S. and T.N. Mayadas1, TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney International, 2015. 87(2): p. 281–296. https://doi.org/10.1038/ki.2014.285.

42.

Clark, A.R. and A. Toker1, Signalling specificity in the Akt pathway in breast cancer. Biochem Soc Trans, 2014. 42(5): p. 1349–55. https://doi.org/10.1042/bst20140160.

43.

Berns K, Horlings HM, Hennessy BT, et al. 1, A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395–402. https://doi.org/10.1016/j.ccr.2007.08.030.CrossRefPubMed

44.

Esteva FJ, Guo H, Zhang S, et al. 1, PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol. 2010;177(4):1647–56. https://doi.org/10.2353/ajpath.2010.090885.CrossRefPubMedPubMedCentral

45.

Prueitt RL, Boersma BJ, Howe TM, et al. 1, Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer. 2007;120(4):796–805. https://doi.org/10.1002/ijc.22336.CrossRefPubMed

46.

Yang, F., N. Zhao, and N. Wu1, TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage. Mol Med Rep, 2017. 16(3): p. 2962–2968. https://doi.org/10.3892/mmr.2017.6898.

47.

Shin, E. and J.S. Koo1, Glucose Metabolism and Glucose Transporters in Breast Cancer. Front Cell Dev Biol, 2021. 9: p. 728759. https://doi.org/10.3389/fcell.2021.728759.

48.

Liu P, Cheng H, Roberts TM, et al. 1, Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–44. https://doi.org/10.1038/nrd2926.CrossRefPubMedPubMedCentral

49.

Zhou R, Chen H, Chen J, et al. 1, Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway. BMC Complement Altern Med. 2018;18(1):83. https://doi.org/10.1186/s12906-018-2148-2.CrossRefPubMedPubMedCentral

50.

Paplomata, E. and R. O'Regan1, The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. Ther Adv Med Oncol, 2014. 6(4): p. 154–66. https://doi.org/10.1177/1758834014530023.

51.

Zhou, X., M. Tan, V. Stone Hawthorne, et al.1, Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. Clinical Cancer Research, 2004. 10(20): p. 6779–6788. https://doi.org/10.1158/1078-0432.CCR-04-0112.

52.

Hare SH, Harvey AJ. mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res. 2017;7(3):383–404.PubMedPubMedCentral

53.

Huang, S.1, mTOR Signaling in Metabolism and Cancer. Cells, 2020. 9(10): p. https://doi.org/10.3390/cells9102278.

54.

Zhang R, Xu Y, Ekman N, et al. 1, Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem. 2003;278(51):51267–76. https://doi.org/10.1074/jbc.M310678200.CrossRefPubMed

55.

Pan S, An P, Zhang R, et al. 1, Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol. 2002;22(21):7512–23. https://doi.org/10.1128/mcb.22.21.7512-7523.2002.CrossRefPubMedPubMedCentral

56.

Rajendran, P., R. Ben Ammar, F.J. Al-Saeedi, et al.1, Thidiazuron decreases epithelial-mesenchymal transition activity through the NF-kB and PI3K/AKT signalling pathways in breast cancer. Journal of Cellular and Molecular Medicine, 2020. 24(24): p. 14525–14538. https://doi.org/10.1111/jcmm.16079.

57.

Lin C-H, Chang C-Y, Lee K-R, et al. 1, Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway. BMC Cancer. 2015;15(1):958. https://doi.org/10.1186/s12885-015-1965-7.CrossRefPubMedPubMedCentral

58.

Cabal-Hierro L, Rodríguez M, Artime N, et al. 1, TRAF-mediated modulation of NF-kB AND JNK Activation by TNFR2. Cell Signal. 2014;26(12):2658–66. https://doi.org/10.1016/j.cellsig.2014.08.011.CrossRefPubMed

59.

Jupp OJ, McFarlane SM, Anderson HM, et al. 1, Type II tumour necrosis factor-alpha receptor (TNFR2) activates c-Jun N-terminal kinase (JNK) but not mitogen-activated protein kinase (MAPK) or p38 MAPK pathways. Biochem J. 2001;359(Pt 3):525–35. https://doi.org/10.1042/0264-6021:3590525.CrossRefPubMedPubMedCentral

60.

Yeh, C.-T., C.-H. Wu, and G.-C. Yen1, Ursolic acid, a naturally occurring triterpenoid, suppresses migration and invasion of human breast cancer cells by modulating c-Jun N-terminal kinase, Akt and mammalian target of rapamycin signaling. Molecular Nutrition & Food Research, 2010. 54(9): p. 1285–1295. https://doi.org/10.1002/mnfr.200900414.

61.

Kufe, D.W.1, MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene, 2013. 32(9): p. 1073–1081. https://doi.org/10.1038/onc.2012.158.

62.

Hattrup, C.L. and S.J. Gendler1, MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Res, 2006. 8(4): p. R37. https://doi.org/10.1186/bcr1515.

63.

Rao, A. and D.R. Herr1, G protein-coupled receptor GPR19 regulates E-cadherin expression and invasion of breast cancer cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2017. 1864(7): p. 1318–1327. https://doi.org/10.1016/j.bbamcr.2017.05.001.

64.

Roberts, P.J. and C.J. Der1, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007. 26(22): p. 3291–3310. https://doi.org/10.1038/sj.onc.1210422.

65.

Ouyang L, Chen Y, Wang X-Y, et al. 1, Polygonatum odoratum lectin induces apoptosis and autophagy via targeting EGFR-mediated Ras-Raf-MEK-ERK pathway in human MCF-7 breast cancer cells. Phytomedicine. 2014;21(12):1658–65. https://doi.org/10.1016/j.phymed.2014.08.002.CrossRefPubMed

66.

Jiang L, Wang P, Sun Y-J, et al. 1, Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res. 2019;38(1):265. https://doi.org/10.1186/s13046-019-1251-7.CrossRefPubMedPubMedCentral

67.

Guo YJ, Pan WW, Liu SB, et al. 1, ERK/MAPK signalling pathway and tumorigenesis (Review). Exp Ther Med. 2020;19(3):1997–2007. https://doi.org/10.3892/etm.2020.8454.CrossRefPubMedPubMedCentral

68.

Whitmarsh, A.J. and R.J. Davis1, Transcription factor AP-1 regulation by mitogen-activated protein kinase signal transduction pathways. J Mol Med (Berl), 1996. 74(10): p. 589–607. https://doi.org/10.1007/s001090050063.

69.

Niu, Y., J. Xu, and T. Sun1, Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. J Cancer, 2019. 10(22): p. 5504–5517. https://doi.org/10.7150/jca.32628.

70.

Chen Z, Wang Y, Warden C, et al. 1, Cross-talk between ER and HER2 regulates c-MYC-mediated glutamine metabolism in aromatase inhibitor resistant breast cancer cells. J Steroid Biochem Mol Biol. 2015;149:118–27. https://doi.org/10.1016/j.jsbmb.2015.02.004.CrossRefPubMedPubMedCentral

71.

Shajahan-Haq AN, Cook KL, Schwartz-Roberts JL, et al. 1, MYC regulates the unfolded protein response and glucose and glutamine uptake in endocrine resistant breast cancer. Mol Cancer. 2014;13(1):239. https://doi.org/10.1186/1476-4598-13-239.CrossRefPubMedPubMedCentral

72.

Ndlovu MN, Van Lint C, Van Wesemael K, et al. 1, Hyperactivated NF-κB and AP-1 Transcription Factors Promote Highly Accessible Chromatin and Constitutive Transcription across the Interleukin-6 Gene Promoter in Metastatic Breast Cancer Cells. Mol Cell Biol. 2009;29(20):5488–504. https://doi.org/10.1128/MCB.01657-08.CrossRefPubMed

73.

Fouad TM, Kogawa T, Reuben JM, et al. 1, The role of inflammation in inflammatory breast cancer. Adv Exp Med Biol. 2014;816:53–73. https://doi.org/10.1007/978-3-0348-0837-8_3.CrossRefPubMed

74.

Funakoshi-Tago M, Shimizu T, Tago K, et al. 1, Celecoxib potently inhibits TNFα-induced nuclear translocation and activation of NF-κB. Biochem Pharmacol. 2008;76(5):662–71. https://doi.org/10.1016/j.bcp.2008.06.015.CrossRefPubMed

75.

Kim MJ, Kim HS, Lee SH, et al. 1, NDRG2 controls COX-2/PGE₂-mediated breast cancer cell migration and invasion. Mol Cells. 2014;37(10):759–65. https://doi.org/10.14348/molcells.2014.0232.CrossRefPubMedPubMedCentral

76.

Zhou BP, Hu MCT, Miller SA, et al. 1, HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway*. J Biol Chem. 2000;275(11):8027–31. https://doi.org/10.1074/jbc.275.11.8027.CrossRefPubMed

77.

Hamilton KE, Simmons JG, Ding S, et al. 1, Cytokine Induction of Tumor Necrosis Factor Receptor 2 Is Mediated by STAT3 in Colon Cancer Cells. Mol Cancer Res. 2011;9(12):1718–31. https://doi.org/10.1158/1541-7786.MCR-10-0210.CrossRefPubMedPubMedCentral

78.

D'Ignazio, L., M. Batie, and S. Rocha1, Hypoxia and Inflammation in Cancer, Focus on HIF and NF-κB. Biomedicines, 2017. 5(2): p. https://doi.org/10.3390/biomedicines5020021.

79.

Naik A, Al-Yahyaee A, Abdullah N, et al. 1, Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells. BMC Cancer. 2018;18(1):533. https://doi.org/10.1186/s12885-018-4446-y.CrossRefPubMedPubMedCentral

80.

Luo M, Hou L, Li J, et al. 1, VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin. Cancer Lett. 2016;373(1):1–11. https://doi.org/10.1016/j.canlet.2016.01.010.CrossRefPubMed

81.

Micheau O, Lens S, Gaide O, et al. 1, NF-κB Signals Induce the Expression of c-FLIP. Mol Cell Biol. 2001;21(16):5299–305. https://doi.org/10.1128/MCB.21.16.5299-5305.2001.CrossRefPubMedPubMedCentral

82.

Depuydt B, Van Loo G, Vandenabeele P, et al. 1, Induction of apoptosis by TNF receptor 2 in a T-cell hybridoma is FADD dependent and blocked by caspase-8 inhibitors. J Cell Sci. 2005;118(3):497–504. https://doi.org/10.1242/jcs.01640.CrossRefPubMed

83.

Watson, C.J.1, Key stages in mammary gland development - Involution: apoptosis and tissue remodelling that convert the mammary gland from milk factory to a quiescent organ. Breast Cancer Research, 2006. 8(2): p. 203. https://doi.org/10.1186/bcr1401.

84.

Beinke, S. and S.C. Ley1, Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J, 2004. 382(Pt 2): p. 393–409. https://doi.org/10.1042/bj20040544.

85.

Liu H, Yang J, Yuan Y, et al. 1, Regulation of Mcl-1 by constitutive activation of NF-kappaB contributes to cell viability in human esophageal squamous cell carcinoma cells. BMC Cancer. 2014;14(1):98. https://doi.org/10.1186/1471-2407-14-98.CrossRefPubMedPubMedCentral

86.

Wang CY, Guttridge DC, Mayo MW, et al. 1, NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol. 1999;19(9):5923–9. https://doi.org/10.1128/mcb.19.9.5923.CrossRefPubMedPubMedCentral

87.

Frazzi, R.1, BIRC3 and BIRC5: multi‐faceted inhibitors in cancer. Cell & Bioscience, 2021. 11(1): p. 8. https://doi.org/10.1186/s13578-020-00521-0.

88.

Reilly LA, Kruse EA, Puthalakath H, et al. 1, MEK/ERK-Mediated Phosphorylation of Bim Is Required to Ensure Survival of T and B Lymphocytes during Mitogenic Stimulation. J Immunol. 2009;183(1):261. https://doi.org/10.4049/jimmunol.0803853.CrossRef

89.

Callahan, R. and S. Hurvitz1, Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol, 2011. 23(1): p. 37–43. https://doi.org/10.1097/gco.0b013e3283414e87.

90.

Saha, T., J. Solomon, A.O. Samson, et al.1, Invasion and Metastasis as a Central Hallmark of Breast Cancer. J Clin Med, 2021. 10(16): p. https://doi.org/10.3390/jcm10163498.

91.

Yeeravalli, R. and A. Das1, Molecular mediators of breast cancer metastasis. Hematology/Oncology and Stem Cell Therapy, 2021. 14(4): p. 275–289. https://doi.org/10.1016/j.hemonc.2021.02.002.

92.

Ham B, Wang N, D’Costa Z, et al. 1, TNF Receptor-2 Facilitates an Immunosuppressive Microenvironment in the Liver to Promote the Colonization and Growth of Hepatic Metastases. Can Res. 2015;75(24):5235–47. https://doi.org/10.1158/0008-5472.CAN-14-3173.CrossRef

93.

Sasi SP, Yan X, Enderling H, et al. 1, Breaking the “harmony” of TNF-α signaling for cancer treatment. Oncogene. 2012;31(37):4117–27. https://doi.org/10.1038/onc.2011.567.CrossRefPubMed

94.

Chopra M, Riedel SS, Biehl M, et al. 1, Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis. 2013;34(6):1296–303. https://doi.org/10.1093/carcin/bgt038.CrossRefPubMed

95.

Huber MA, Azoitei N, Baumann B, et al. 1, NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Investig. 2004;114(4):569–81. https://doi.org/10.1172/JCI21358.CrossRefPubMedPubMedCentral

96.

Pires BRB, Mencalha AL, Ferreira GM, et al. 1, NF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells. PLoS ONE. 2017;12(1): e0169622. https://doi.org/10.1371/journal.pone.0169622.CrossRefPubMedPubMedCentral

97.

Wang, W., S.A. Nag, and R. Zhang1, Targeting the NFκB signaling pathways for breast cancer prevention and therapy. Curr Med Chem, 2015. 22(2): p. 264–89. https://doi.org/10.2174/0929867321666141106124315.

98.

Craene, B.D. and G. Berx1, Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews Cancer, 2013. 13(2): p. 97–110. https://doi.org/10.1038/nrc3447.

99.

García-Román, J. and A. Zentella-Dehesa1, Vascular permeability changes involved in tumor metastasis. Cancer Letters, 2013. 335(2): p. 259–269. https://doi.org/10.1016/j.canlet.2013.03.005.

100.

Park, M., D. Kim, S. Ko, et al.1, Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci, 2022. 23(12): p. https://doi.org/10.3390/ijms23126806.

101.

Di Russo S, Liberati FR, Riva A, et al. 1, Beyond the barrier: the immune-inspired pathways of tumor extravasation. Cell Communication and Signaling. 2024;22(1):104. https://doi.org/10.1186/s12964-023-01429-1.CrossRefPubMedPubMedCentral

102.

Yu PF, Huang Y, Han YY, et al. 1, TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2(+) neutrophils. Oncogene. 2017;36(4):482–90. https://doi.org/10.1038/onc.2016.217.CrossRefPubMed

103.

Qian B, Deng Y, Im JH, et al. 1, A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE. 2009;4(8): e6562. https://doi.org/10.1371/journal.pone.0006562.CrossRefPubMedPubMedCentral

104.

Jiang WG, Sanders AJ, Katoh M, et al. 1, Tissue invasion and metastasis: Molecular, biological and clinical perspectives. Semin Cancer Biol. 2015;35:S244–75. https://doi.org/10.1016/j.semcancer.2015.03.008.CrossRefPubMed

105.

Kuang W, Deng Q, Deng C, et al. 1, Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2. Am J Transl Res. 2017;9(8):3816–26.PubMedPubMedCentral

106.

Lee, J.S., C.E. Tocheny, and L.M. Shaw1, The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target. Life (Basel), 2022. 12(12): p. https://doi.org/10.3390/life12121992.

107.

Song, K. and M. Farzaneh1, Signaling pathways governing breast cancer stem cells behavior. Stem Cell Research & Therapy, 2021. 12(1): p. 245. https://doi.org/10.1186/s13287-021-02321-w.

108.

Giovannelli P, Di Donato M, Galasso G, et al. 1, Breast cancer stem cells: The role of sex steroid receptors. World J Stem Cells. 2019;11(9):594–603. https://doi.org/10.4252/wjsc.v11.i9.594.CrossRefPubMedPubMedCentral

109.

Walker, M.R., H.L. Goel, D. Mukhopadhyay, et al.1, O-linked α2,3 sialylation defines stem cell populations in breast cancer. Science Advances. 8(1): p. eabj9513. https://doi.org/10.1126/sciadv.abj9513.

110.

Yang L, Shi P, Zhao G, et al. 1, Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8. https://doi.org/10.1038/s41392-020-0110-5.CrossRefPubMedPubMedCentral

111.

Liu W, Lu X, Shi P, et al. 1, TNF-α increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-κB pathway. Sci Rep. 2020;10(1):1804. https://doi.org/10.1038/s41598-020-58642-y.CrossRefPubMedPubMedCentral

112.

Narasimhan, H., F. Ferraro, A. Bleilevens, et al.1, Tumor Necrosis Factor-α (TNFα) Stimulate Triple-Negative Breast Cancer Stem Cells to Promote Intratumoral Invasion and Neovasculogenesis in the Liver of a Xenograft Model. Biology (Basel), 2022. 11(10): p. https://doi.org/10.3390/biology11101481.

113.

Storci G, Sansone P, Mari S, et al. 1, TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol. 2010;225(3):682–91. https://doi.org/10.1002/jcp.22264.CrossRefPubMedPubMedCentral

114.

Zhang H, Lu H, Xiang L, et al. 1, HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A. 2015;112(45):E6215–23. https://doi.org/10.1073/pnas.1520032112.CrossRefPubMedPubMedCentral

115.

Li Y, Kong L, Yang Y, et al. 1, Mutant TNFalpha negatively regulates human breast cancer stem cells from MCF7 in vitro. Cancer Biol Ther. 2007;6(9):1480–9. https://doi.org/10.4161/cbt.6.9.4885.CrossRefPubMed

116.

Bradley JR, Wang J, Pacey S, et al. 1, Tumor necrosis factor receptor-2 signaling pathways promote survival of cancer stem-like CD133+ cells in clear cell renal carcinoma. FASEB BioAdvances. 2020;2(2):126–44. https://doi.org/10.1096/fba.2019-00071.CrossRefPubMedPubMedCentral

117.

Flores-Huerta, N., M.B. Silva-Cázares, L.A. Arriaga-Pizano, et al.1, LncRNAs and microRNAs as Essential Regulators of Stemness in Breast Cancer Stem Cells. Biomolecules, 2021. 11(3): p. https://doi.org/10.3390/biom11030380.

118.

Ferrandino F, Grazioli P, Bellavia D, et al. 1, Notch and NF-κB: Coach and Players of Regulatory T-Cell Response in Cancer. Front Immunol. 2018;9:2165. https://doi.org/10.3389/fimmu.2018.02165.CrossRefPubMedPubMedCentral

119.

Yamashita M, Otsuka F, Mukai T, et al. 1, Simvastatin antagonizes tumor necrosis factor-α inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. J Endocrinol. 2008;196(3):601–13. https://doi.org/10.1677/JOE-07-0532.CrossRefPubMed

120.

Johnson, D.E., R.A. O'Keefe, and J.R. Grandis1, Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews Clinical Oncology, 2018. 15(4): p. 234–248. https://doi.org/10.1038/nrclinonc.2018.8.

121.

Yousefnia, S., F. Seyed Forootan, S. Seyed Forootan, et al.1, Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells. Front Oncol, 2020. 10: p. 452. https://doi.org/10.3389/fonc.2020.00452.

122.

Marotta LLC, Almendro V, Marusyk A, et al. 1, The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors. J Clin Investig. 2011;121(7):2723–35. https://doi.org/10.1172/JCI44745.CrossRefPubMedPubMedCentral

123.

Zhang T, Zhou H, Wang K, et al. 1, Role, molecular mechanism and the potential target of breast cancer stem cells in breast cancer development. Biomed Pharmacother. 2022;147: 112616. https://doi.org/10.1016/j.biopha.2022.112616.CrossRefPubMed

124.

Bayik, D. and J.D. Lathia1, Cancer stem cell-immune cell crosstalk in tumour progression. Nat Rev Cancer, 2021. 21(8): p. 526–536. https://doi.org/10.1038/s41568-021-00366-w.

125.

Gilkes, D.M. and G.L. Semenza1, Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol, 2013. 9(11): p. 1623–36. https://doi.org/10.2217/fon.13.92.

126.

Jampasri, S., S. Reabroi, D. Tungmunnithum, et al.1, Plumbagin Suppresses Breast Cancer Progression by Downregulating HIF-1α Expression via a PI3K/Akt/mTOR Independent Pathway under Hypoxic Condition. Molecules, 2022. 27(17): p. https://doi.org/10.3390/molecules27175716.

127.

Balamurugan, K.1, HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer, 2016. 138(5): p. 1058–66. https://doi.org/10.1002/ijc.29519.

128.

D'Ignazio, L., D. Bandarra, and S. Rocha1, NF-κB and HIF crosstalk in immune responses. The FEBS Journal, 2016. 283(3): p. 413–424. https://doi.org/10.1111/febs.13578.

129.

Manresa, M.C. and C.T. Taylor1, Hypoxia Inducible Factor (HIF) Hydroxylases as Regulators of Intestinal Epithelial Barrier Function. Cellular and Molecular Gastroenterology and Hepatology, 2017. 3(3): p. 303–315. https://doi.org/10.1016/j.jcmgh.2017.02.004.

130.

Esencay, M., E.W. Newcomb, and D. Zagzag1, HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration. J Neurooncol, 2010. 99(1): p. 33–40. https://doi.org/10.1007/s11060-010-0111-2.

131.

Antonangeli F, Natalini A, Garassino MC, et al. 1, Regulation of PD-L1 Expression by NF-κB in Cancer. Front Immunol. 2020;11: 584626. https://doi.org/10.3389/fimmu.2020.584626.CrossRefPubMedPubMedCentral

132.

Oeckinghaus, A., M.S. Hayden, and S. Ghosh1, Crosstalk in NF-κB signaling pathways. Nature Immunology, 2011. 12(8): p. 695–708. https://doi.org/10.1038/ni.2065.

133.

Kaidi, A., A.C. Williams, and C. Paraskeva1, Interaction between β-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nature Cell Biology, 2007. 9(2): p. 210–217. https://doi.org/10.1038/ncb1534.

134.

Siegmund, D., J. Wagner, and H. Wajant1, TNF Receptor Associated Factor 2 (TRAF2) Signaling in Cancer. Cancers (Basel), 2022. 14(16): p. https://doi.org/10.3390/cancers14164055.

135.

Minet E, Ernest I, Michel G, et al. 1, HIF1A Gene Transcription Is Dependent on a Core Promoter Sequence Encompassing Activating and Inhibiting Sequences Located Upstream from the Transcription Initiation Site and cis Elements Located within the 5′UTR. Biochem Biophys Res Commun. 1999;261(2):534–40. https://doi.org/10.1006/bbrc.1999.0995.CrossRefPubMed

136.

van Uden, P., N.S. Kenneth, and S. Rocha1, Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J, 2008. 412(3): p. 477–84. https://doi.org/10.1042/bj20080476.

137.

Bonello S, Zähringer C, BelAiba RS, et al. 1, Reactive oxygen species activate the HIF-1alpha promoter via a functional NFkappaB site. Arterioscler Thromb Vasc Biol. 2007;27(4):755–61. https://doi.org/10.1161/01.ATV.0000258979.92828.bc.CrossRefPubMed

138.

Sun H, Li X-B, Meng Y, et al. 1, TRAF6 Upregulates Expression of HIF-1α and Promotes Tumor Angiogenesis. Can Res. 2013;73(15):4950–9. https://doi.org/10.1158/0008-5472.CAN-13-0370.CrossRef

139.

Chen, W., Y. Qin, and S. Liu1, Cytokines, breast cancer stem cells (BCSCs) and chemoresistance. Clinical and Translational Medicine, 2018. 7(1): p. e27. https://doi.org/10.1186/s40169-018-0205-6.

140.

Mukherjee D, Zhao J. The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res. 2013;3(1):46–57.PubMedPubMedCentral

141.

Roberts, P.J. and C.J. Der1, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 2007. 26(22): p. 3291–310. https://doi.org/10.1038/sj.onc.1210422.

142.

Cummins EP, Berra E, Comerford KM, et al. 1, Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A. 2006;103(48):18154–9. https://doi.org/10.1073/pnas.0602235103.CrossRefPubMedPubMedCentral

143.

Cai X, Wang R, Zhu J, et al. 1, Factor inhibiting HIF negatively regulates antiviral innate immunity via hydroxylation of IKKϵ. Cell Rep. 2024;43(1): 113606. https://doi.org/10.1016/j.celrep.2023.113606.CrossRefPubMed

144.

Al-Lamki RS, Lu W, Wang J, et al. 1, TNF, acting through inducibly expressed TNFR2, drives activation and cell cycle entry of c-Kit+ cardiac stem cells in ischemic heart disease. Stem Cells. 2013;31(9):1881–92. https://doi.org/10.1002/stem.1433.CrossRefPubMed

145.

Iliopoulos, D., H.A. Hirsch, and K. Struhl1, An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell Transformation. Cell, 2009. 139(4): p. 693–706. https://doi.org/10.1016/j.cell.2009.10.014.

146.

Wilbert ML, Huelga SC, Kapeli K, et al. 1, LIN28 binds messenger RNAs at GGAGA motifs and regulates splicing factor abundance. Mol Cell. 2012;48(2):195–206. https://doi.org/10.1016/j.molcel.2012.08.004.CrossRefPubMedPubMedCentral

147.

Weng M, Feng Y, He Y, et al. 1, Hypoxia-Induced LIN28A mRNA Promotes the Metastasis of Colon Cancer in a Protein-Coding-Independent Manner. Front Cell Dev Biol. 2021;9: 642930. https://doi.org/10.3389/fcell.2021.642930.CrossRefPubMedPubMedCentral

148.

Xiang, Q., B. Yang, L. Li, et al.1, Critical role of Lin28-TNFR2 signalling in cardiac stem cell activation and differentiation. Journal of Cellular and Molecular Medicine, 2019. 23(4): p. 0–0. https://doi.org/10.1111/jcmm.14202.

149.

Chatterjee, S., B. Behnam Azad, and S. Nimmagadda1, The intricate role of CXCR4 in cancer. Adv Cancer Res, 2014. 124: p. 31–82. https://doi.org/10.1016/b978-0-12-411638-2.00002-1.

150.

Soysal, S.D., A. Tzankov, and S.E. Muenst1, Role of the Tumor Microenvironment in Breast Cancer. Pathobiology, 2015. 82(3–4): p. 142–152. https://doi.org/10.1159/000430499.

151.

Mortezaee, K.1, CXCL12/CXCR4 axis in the microenvironment of solid tumors: A critical mediator of metastasis. Life Sciences, 2020. 249: p. 117534. https://doi.org/10.1016/j.lfs.2020.117534.

152.

Ohira S, Sasaki M, Harada K, et al. 1, Possible Regulation of Migration of Intrahepatic Cholangiocarcinoma Cells by Interaction of CXCR4 Expressed in Carcinoma Cells with Tumor Necrosis Factor-α and Stromal-Derived Factor-1 Released in Stroma. Am J Pathol. 2006;168(4):1155–68. https://doi.org/10.2353/ajpath.2006.050204.CrossRefPubMedPubMedCentral

153.

Balkwill, F.1, TNF-α in promotion and progression of cancer. Cancer and Metastasis Reviews, 2006. 25(3): p. 409–416. https://doi.org/10.1007/s10555-006-9005-3.

154.

Balkwill, F.1, The significance of cancer cell expression of the chemokine receptor CXCR4. Seminars in Cancer Biology, 2004. 14(3): p. 171–179. https://doi.org/10.1016/j.semcancer.2003.10.003.

155.

Xu C, Zhao H, Chen H, et al. 1, CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953–64. https://doi.org/10.2147/dddt.S84932.CrossRefPubMedPubMedCentral

156.

Dunn LK, Mohammad KS, Fournier PG, et al. 1, Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE. 2009;4(9): e6896. https://doi.org/10.1371/journal.pone.0006896.CrossRefPubMedPubMedCentral

157.

Patel JR, Williams JL, Muccigrosso MM, et al. 1, Astrocyte TNFR2 is required for CXCL12-mediated regulation of oligodendrocyte progenitor proliferation and differentiation within the adult CNS. Acta Neuropathol. 2012;124(6):847–60. https://doi.org/10.1007/s00401-012-1034-0.CrossRefPubMedPubMedCentral

158.

Benovic, J.L. and A. Marchese1, A new key in breast cancer metastasis. Cancer Cell, 2004. 6(5): p. 429–430. https://doi.org/10.1016/j.ccr.2004.10.017.

159.

Bates JP, Derakhshandeh R, Jones L, et al. 1, Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018;18(1):556. https://doi.org/10.1186/s12885-018-4441-3.CrossRefPubMedPubMedCentral

160.

Planes-Laine, G., P. Rochigneux, F. Bertucci, et al.1, PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. Cancers (Basel), 2019. 11(7): p. https://doi.org/10.3390/cancers11071033.

161.

Huang W, Ran R, Shao B, et al. 1, Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. Breast Cancer Res Treat. 2019;178(1):17–33. https://doi.org/10.1007/s10549-019-05371-0.CrossRefPubMed

162.

Baptista MZ, Sarian LO, Derchain SFM, et al. 1, Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol. 2016;47(1):78–84. https://doi.org/10.1016/j.humpath.2015.09.006.CrossRefPubMed

163.

Miglietta F, Griguolo G, Guarneri V, et al. 1, Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. Oncologist. 2019;24(11):e1055–69. https://doi.org/10.1634/theoncologist.2019-0197.CrossRefPubMedPubMedCentral

164.

Arias-Pulido H, Cimino-Mathews A, Chaher N, et al. 1, The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Res Treat. 2018;171(2):273–82. https://doi.org/10.1007/s10549-018-4834-7.CrossRefPubMedPubMedCentral

165.

Cimino-Mathews A, Thompson E, Taube JM, et al. 1, PD-L1 (B7–H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016;47(1):52–63. https://doi.org/10.1016/j.humpath.2015.09.003.CrossRefPubMed

166.

Dadiani M, Necula D, Kahana-Edwin S, et al. 1, TNFR2+ TILs are significantly associated with improved survival in triple-negative breast cancer patients. Cancer Immunol Immunother. 2020;69(7):1315–26. https://doi.org/10.1007/s00262-020-02549-0.CrossRefPubMedPubMedCentral

167.

Baram, T., N. Oren, N. Erlichman, et al.1, Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNFα Receptors in Human Triple-Negative Breast Cancer. Cancers (Basel), 2022. 14(14): p. https://doi.org/10.3390/cancers14143513.

168.

Chen S, Crabill GA, Pritchard TS, et al. 1, Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer. 2019;7(1):305. https://doi.org/10.1186/s40425-019-0770-2.CrossRefPubMedPubMedCentral

169.

You W, Shang B, Sun J, et al. 1, Mechanistic insight of predictive biomarkers for antitumor PD-1/PD-L1 blockade: A paradigm shift towards immunome evaluation (Review). Oncol Rep. 2020;44(2):424–37. https://doi.org/10.3892/or.2020.7643.CrossRefPubMedPubMedCentral

170.

Wang F, Schwarz BT, Graham WV, et al. 1, IFN-gamma-induced TNFR2 expression is required for TNF-dependent intestinal epithelial barrier dysfunction. Gastroenterology. 2006;131(4):1153–63. https://doi.org/10.1053/j.gastro.2006.08.022.CrossRefPubMed

171.

Chen J, Jiang CC, Jin L, et al. 1, Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann Oncol. 2016;27(3):409–16. https://doi.org/10.1093/annonc/mdv615.CrossRefPubMed

172.

Jiang X, Wang J, Deng X, et al. 1, Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. https://doi.org/10.1186/s12943-018-0928-4.CrossRefPubMedPubMedCentral

173.

Vranic S, Cyprian FS, Gatalica Z, et al. 1, PD-L1 status in breast cancer: Current view and perspectives. Semin Cancer Biol. 2021;72:146–54. https://doi.org/10.1016/j.semcancer.2019.12.003.CrossRefPubMed

174.

Asgarova A, Asgarov K, Godet Y, et al. 1, PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. OncoImmunology. 2018;7(5): e1423170. https://doi.org/10.1080/2162402X.2017.1423170.CrossRefPubMedPubMedCentral

175.

Xiaozhen Z, Mengyi L, Jian X, et al. 1, Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors. J Immunother Cancer. 2022;10(3): e003982. https://doi.org/10.1136/jitc-2021-003982.CrossRef

176.

Mohd Idris, R.A., A. Mussa, S. Ahmad, et al.1, The Effects of Tamoxifen on Tolerogenic Cells in Cancer. Biology (Basel), 2022. 11(8): p. https://doi.org/10.3390/biology11081225.

177.

Schmidt, A., N. Oberle, and P.H. Krammer1, Molecular mechanisms of treg-mediated T cell suppression. Front Immunol, 2012. 3: p. 51. https://doi.org/10.3389/fimmu.2012.00051.

178.

Chen X, Bäumel M, Männel DN, et al. 1, Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007;179(1):154–61. https://doi.org/10.4049/jimmunol.179.1.154.CrossRefPubMed

179.

Zou H, Li R, Hu H, et al. 1, Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. Front Immunol. 2018;9:594. https://doi.org/10.3389/fimmu.2018.00594.CrossRefPubMedPubMedCentral

180.

Yang S, Xie C, Chen Y, et al. 1, Differential roles of TNFα-TNFR1 and TNFα-TNFR2 in the differentiation and function of CD4+Foxp3+ induced Treg cells in vitro and in vivo periphery in autoimmune diseases. Cell Death Dis. 2019;10(1):27. https://doi.org/10.1038/s41419-018-1266-6.CrossRefPubMedPubMedCentral

181.

Mengmeng J, Yang Y, Liling N, et al. 1, MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2. J Immunother Cancer. 2022;10(11): e005241. https://doi.org/10.1136/jitc-2022-005241.CrossRef

182.

Tseng W-Y, Huang Y-S, Clanchy F, et al. 1, TNF receptor 2 signaling prevents DNA methylation at the Foxp3 promoter and prevents pathogenic conversion of regulatory T cells. Proc Natl Acad Sci. 2019;116(43):21666–72. https://doi.org/10.1073/pnas.1909687116.CrossRefPubMedPubMedCentral

183.

Chen X, Subleski JJ, Kopf H, et al. 1, Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol. 2008;180(10):6467–71. https://doi.org/10.4049/jimmunol.180.10.6467.CrossRefPubMed

184.

Chen X, Du Y, Lin X, et al. 1, CD4+CD25+ regulatory T cells in tumor immunity. Int Immunopharmacol. 2016;34:244–9. https://doi.org/10.1016/j.intimp.2016.03.009.CrossRefPubMed

185.

Chang L-Y, Lin Y-C, Chiang J-M, et al. 1, Blockade of TNF-α signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. OncoImmunology. 2015;4(10): e1040215. https://doi.org/10.1080/2162402X.2015.1040215.CrossRefPubMedPubMedCentral

186.

Plitas G, Konopacki C, Wu K, et al. 1, Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity. 2016;45(5):1122–34. https://doi.org/10.1016/j.immuni.2016.10.032.CrossRefPubMedPubMedCentral

187.

Ghods A, Mehdipour F, Shariat M, et al. 1, Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4+ T cells in the draining lymph nodes of breast cancer. Mol Immunol. 2021;137:52–6. https://doi.org/10.1016/j.molimm.2021.06.013.CrossRefPubMed

188.

Ghods A, Ghaderi A, Shariat M, et al. 1, TNFR2 but not TNFR1 is the main TNFR expressed by B and T lymphocytes in breast cancer draining lymph nodes. Immunol Lett. 2019;209:36–44. https://doi.org/10.1016/j.imlet.2019.03.013.CrossRefPubMed

189.

Urbano PCM, Koenen H, Joosten I, et al. 1, An Autocrine TNFα-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability In Vitro. Front Immunol. 2018;9:573. https://doi.org/10.3389/fimmu.2018.00573.CrossRefPubMedPubMedCentral

190.

Inoue M, Yamashita K, Tsuji Y, et al. 1, Characterization of a TNFR2-Selective Agonistic TNF-α Mutant and Its Derivatives as an Optimal Regulatory T Cell Expander. J Immunol. 2021;206(8):1740–51. https://doi.org/10.4049/jimmunol.2000871.CrossRefPubMed

191.

He T, Zhao Y, Zhao P, et al. 1, Signaling pathway(s) of TNFR2 required for the immunoregulatory effect of CD4+Foxp3+ regulatory T cells. Int Immunopharmacol. 2022;108: 108823. https://doi.org/10.1016/j.intimp.2022.108823.CrossRefPubMed

192.

Grinberg-Bleyer Y, Caron R, Seeley JJ, et al. 1, The Alternative NF-κB Pathway in Regulatory T Cell Homeostasis and Suppressive Function. J Immunol. 2018;200(7):2362–71. https://doi.org/10.4049/jimmunol.1800042.CrossRefPubMed

193.

Yu T, Li YJ, Bian AH, et al. The regulatory role of activating transcription factor 2 in inflammation. Mediators Inflamm. 2014;2014:950472. https://doi.org/10.1155/2014/950472.

194.

Recio, J.A. and G. Merlino1, Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene, 2002. 21(7): p. 1000–1008. https://doi.org/10.1038/sj.onc.1205150.

195.

Qi T, Luo Y, Cui W, et al. 1, Crosstalk between the CBM complex/NF-κB and MAPK/P27 signaling pathways of regulatory T cells contributes to the tumor microenvironment. Front Cell Dev Biol. 2022;10: 911811. https://doi.org/10.3389/fcell.2022.911811.CrossRefPubMedPubMedCentral

196.

Nie, Y., J. He, H. Shirota, et al.1, Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer. Science Signaling, 2018. 11(511): p. eaan0790. https://doi.org/10.1126/scisignal.aan0790.

197.

de Kivit S, Mensink M, Hoekstra AT, et al. 1, Stable human regulatory T cells switch to glycolysis following TNF receptor 2 costimulation. Nat Metab. 2020;2(10):1046–61. https://doi.org/10.1038/s42255-020-00271-w.CrossRefPubMed

198.

Kim, E.Y. and H.-S. Teh1, Critical Role of TNF Receptor Type-2 (p75) as a Costimulator for IL-2 Induction and T Cell Survival: A Functional Link to CD281. The Journal of Immunology, 2004. 173(7): p. 4500–4509. https://doi.org/10.4049/jimmunol.173.7.4500.

199.

Zhang Q, Cui F, Fang L, et al. 1, TNF-α impairs differentiation and function of TGF-β-induced Treg cells in autoimmune diseases through Akt and Smad3 signaling pathway. J Mol Cell Biol. 2013;5(2):85–98. https://doi.org/10.1093/jmcb/mjs063.CrossRefPubMed

200.

Vaupel, P. and G. Multhoff1, Hypoxia-/HIF-1α-Driven Factors of the Tumor Microenvironment Impeding Antitumor Immune Responses and Promoting Malignant Progression. Adv Exp Med Biol, 2018. 1072: p. 171–175. https://doi.org/10.1007/978-3-319-91287-5_27.

201.

Yan M, Jene N, Byrne D, et al. 1, Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. Breast Cancer Res. 2011;13(2):R47. https://doi.org/10.1186/bcr2869.CrossRefPubMedPubMedCentral

202.

Jin J, Li Y, Zhao Q, et al. 1, Coordinated regulation of immune contexture: crosstalk between STAT3 and immune cells during breast cancer progression. Cell Commun Signal. 2021;19(1):50. https://doi.org/10.1186/s12964-021-00705-2.CrossRefPubMedPubMedCentral

203.

Ye LL, Wei XS, Zhang M, et al. 1, The Significance of Tumor Necrosis Factor Receptor Type II in CD8(+) Regulatory T Cells and CD8(+) Effector T Cells. Front Immunol. 2018;9:583. https://doi.org/10.3389/fimmu.2018.00583.CrossRefPubMedPubMedCentral

204.

Ablamunits V, Henegariu O, Preston-Hurlburt P, et al. 1, NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody. Eur J Immunol. 2011;41(7):1832–42. https://doi.org/10.1002/eji.201041258.CrossRefPubMedPubMedCentral

205.

Sarvaria, A., J.A. Madrigal, and A. Saudemont1, B cell regulation in cancer and anti-tumor immunity. Cellular & Molecular Immunology, 2017. 14(8): p. 662–674. https://doi.org/10.1038/cmi.2017.35.

206.

Olkhanud PB, Damdinsuren B, Bodogai M, et al. 1, Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. Cancer Res. 2011;71(10):3505–15. https://doi.org/10.1158/0008-5472.Can-10-4316.CrossRefPubMedPubMedCentral

207.

Zhang Y, Morgan R, Chen C, et al. 1, Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses. Int Immunol. 2016;28(9):423–33. https://doi.org/10.1093/intimm/dxw007.CrossRefPubMedPubMedCentral

208.

Bodogai, M., C. Lee Chang, K. Wejksza, et al.1, Anti-CD20 antibody promotes cancer escape via enrichment of tumor-evoked regulatory B cells expressing low levels of CD20 and CD137L. Cancer Res, 2013. 73(7): p. 2127–38. https://doi.org/10.1158/0008-5472.Can-12-4184.

209.

Guan H, Lan Y, Wan Y, et al. 1, PD-L1 mediated the differentiation of tumor-infiltrating CD19(+) B lymphocytes and T cells in Invasive breast cancer. Oncoimmunology. 2016;5(2): e1075112. https://doi.org/10.1080/2162402x.2015.1075112.CrossRefPubMed

210.

Cherukuri, A., D.M. Rothstein, B. Clark, et al.1, Immunologic Human Renal Allograft Injury Associates with an Altered IL-10/TNF-α Expression Ratio in Regulatory B Cells. Journal of the American Society of Nephrology, 2014. 25(7): p.

211.

Ammirante M, Luo JL, Grivennikov S, et al. 1, B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464(7286):302–5. https://doi.org/10.1038/nature08782.CrossRefPubMedPubMedCentral

212.

He Y, Qian H, Liu Y, et al. 1, The Roles of Regulatory B Cells in Cancer. J Immunol Res. 2014;2014: 215471. https://doi.org/10.1155/2014/215471.CrossRefPubMedPubMedCentral

213.

Catalán D, Mansilla MA, Ferrier A, et al. 1, Immunosuppressive Mechanisms of Regulatory B Cells. Front Immunol. 2021;12: 611795. https://doi.org/10.3389/fimmu.2021.611795.CrossRefPubMedPubMedCentral

214.

Ticha O, Moos L, Wajant H, et al. 1, Expression of Tumor Necrosis Factor Receptor 2 Characterizes TLR9-Driven Formation of Interleukin-10-Producing B Cells. Front Immunol. 2017;8:1951. https://doi.org/10.3389/fimmu.2017.01951.CrossRefPubMed

215.

Ticha O, Slanina P, Moos L, et al. 1, TNFR2 expression is a hallmark of human memory B cells with suppressive function. Eur J Immunol. 2021;51(5):1195–205. https://doi.org/10.1002/eji.202048988.CrossRefPubMed

216.

Oleinika, K., C. Mauri, and A.D. Salama1, Effector and regulatory B cells in immune-mediated kidney disease. Nature Reviews Nephrology, 2019. 15(1): p. 11–26. https://doi.org/10.1038/s41581-018-0074-7.

217.

Goswami S, Anandhan S, Raychaudhuri D, et al. 1, Myeloid cell-targeted therapies for solid tumours. Nat Rev Immunol. 2023;23(2):106–20. https://doi.org/10.1038/s41577-022-00737-w.CrossRefPubMed

218.

Alshetaiwi H, Pervolarakis N, McIntyre LL, et al. Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020;5(44):6017. https://doi.org/10.1126/sciimmunol.aay6017.CrossRef

219.

Shou D, Wen L, Song Z, et al. 1, Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies. Oncotarget. 2016;7(39):64505–11. https://doi.org/10.18632/oncotarget.11352.CrossRefPubMedPubMedCentral

220.

Groth C, Hu X, Weber R, et al. 1, Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. Br J Cancer. 2019;120(1):16–25. https://doi.org/10.1038/s41416-018-0333-1.CrossRefPubMed

221.

Myeloid-Derived Gabrilovich D, Cells Suppressor. Cancer Immunol Res. 2017;5(1):3–8. https://doi.org/10.1158/2326-6066.CIR-16-0297.CrossRef

222.

Zhao Y, Wu T, Shao S, et al. 1, Phenotype, development, and biological function of myeloid-derived suppressor cells. OncoImmunology. 2016;5(2): e1004983. https://doi.org/10.1080/2162402X.2015.1004983.CrossRefPubMed

223.

de la Cruz-Merino L, Chiesa M, Caballero R, et al. 1, Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. Int Rev Cell Mol Biol. 2017;331:1–53. https://doi.org/10.1016/bs.ircmb.2016.09.008.CrossRefPubMed

224.

Wculek SK, Cueto FJ, Mujal AM, et al. 1, Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7–24. https://doi.org/10.1038/s41577-019-0210-z.CrossRefPubMed

225.

Na YR, Yoon YN, Son DI, et al. 1, Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PLoS ONE. 2013;8(5): e63451. https://doi.org/10.1371/journal.pone.0063451.CrossRefPubMedPubMedCentral

226.

Zhao X, Rong L, Zhao X, et al. 1, TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Investig. 2012;122(11):4094–104. https://doi.org/10.1172/JCI64115.CrossRefPubMedPubMedCentral

227.

Hu X, Li B, Li X, et al. 1, Transmembrane TNF-α Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2. J Immunol. 2014;192(3):1320–31. https://doi.org/10.4049/jimmunol.1203195.CrossRefPubMed

228.

Ba H, Li B, Li X, et al. 1, Transmembrane tumor necrosis factor-α promotes the recruitment of MDSCs to tumor tissue by upregulating CXCR4 expression via TNFR2. Int Immunopharmacol. 2017;44:143–52. https://doi.org/10.1016/j.intimp.2016.12.028.CrossRefPubMed

229.

Li K, Shi H, Zhang B, et al. 1, Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362. https://doi.org/10.1038/s41392-021-00670-9.CrossRefPubMedPubMedCentral

230.

Corzo CA, Condamine T, Lu L, et al. 1, HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207(11):2439–53. https://doi.org/10.1084/jem.20100587.CrossRefPubMedPubMedCentral

231.

Noman MZ, Janji B, Hu S, et al. 1, Tumor-Promoting Effects of Myeloid-Derived Suppressor Cells Are Potentiated by Hypoxia-Induced Expression of miR-210. Cancer Res. 2015;75(18):3771–87. https://doi.org/10.1158/0008-5472.Can-15-0405.CrossRefPubMed

232.

Noman MZ, Desantis G, Janji B, et al. 1, PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med. 2014;211(5):781–90. https://doi.org/10.1084/jem.20131916.CrossRefPubMedPubMedCentral

233.

Li Y-J, Zhang C, Martincuks A, et al. 1, STAT proteins in cancer: orchestration of metabolism. Nat Rev Cancer. 2023. https://doi.org/10.1038/s41568-022-00537-3.CrossRefPubMed

234.

Liu Y, Lai L, Chen Q, et al. 1, MicroRNA-494 Is Required for the Accumulation and Functions of Tumor-Expanded Myeloid-Derived Suppressor Cells via Targeting of PTEN. J Immunol. 2012;188(11):5500–10. https://doi.org/10.4049/jimmunol.1103505.CrossRefPubMed

235.

Ivagnès A, Messaoudene M, Stoll G, et al. 1, TNFR2/BIRC3-TRAF1 signaling pathway as a novel NK cell immune checkpoint in cancer. Oncoimmunology. 2018;7(12): e1386826. https://doi.org/10.1080/2162402x.2017.1386826.CrossRefPubMed

236.

Almishri W, Santodomingo-Garzon T, Le T, et al. 1, TNFα Augments Cytokine-Induced NK Cell IFNγ Production through TNFR2. J Innate Immun. 2016;8(6):617–29. https://doi.org/10.1159/000448077.CrossRefPubMedPubMedCentral

237.

Khan AUH, Ali AK, Marr B, et al. 1, The TNFα/TNFR2 axis mediates natural killer cell proliferation by promoting aerobic glycolysis. Cell Mol Immunol. 2023;20(10):1140–55. https://doi.org/10.1038/s41423-023-01071-4.CrossRefPubMedPubMedCentral

238.

Xu J, Chakrabarti AK, Tan JL, et al. 1, Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk. Blood. 2007;109(8):3333–41. https://doi.org/10.1182/blood-2006-06-026385.CrossRefPubMedPubMedCentral

239.

Tufa DM, Chatterjee D, Low HZ, et al. 1, TNFR2 and IL-12 coactivation enables slanDCs to support NK-cell function via membrane-bound TNF-α. Eur J Immunol. 2014;44(12):3717–28. https://doi.org/10.1002/eji.201444676.CrossRefPubMed

240.

Park MH, Song MJ, Cho MC, et al. 1, Interleukin-32 enhances cytotoxic effect of natural killer cells to cancer cells via activation of death receptor 3. Immunology. 2012;135(1):63–72. https://doi.org/10.1111/j.1365-2567.2011.03513.x.CrossRefPubMedPubMedCentral

241.

Caron G, Delneste Y, Aubry J-P, et al. 1, Human NK cells constitutively express membrane TNF-α (mTNFα) and present mTNFα-dependent cytotoxic activity. Eur J Immunol. 1999;29(11):3588–95. https://doi.org/10.1002/(SICI)1521-4141(199911)29:11%3c3588::AID-IMMU3588%3e3.0.CO;2-O.CrossRefPubMed

242.

You L, Wu W, Wang X, et al. 1, The role of hypoxia-inducible factor 1 in tumor immune evasion. Med Res Rev. 2021;41(3):1622–43. https://doi.org/10.1002/med.21771.CrossRefPubMed

243.

Liu, B., L. Qu, and S. Yan1, Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int 2015. 15(1): p. 106. https://doi.org/10.1186/s12935-015-0260-7.

244.

Yang, H. and C. Chen1, Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des, 2008. 14(14): p. 1443–51. https://doi.org/10.2174/138161208784480144.

245.

Holt D, Ma X, Kundu N, et al. 1, Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother. 2011;60(11):1577–86. https://doi.org/10.1007/s00262-011-1064-9.CrossRefPubMedPubMedCentral

246.

Mehraj U, Dar AH, Wani NA, et al. 1, Tumor microenvironment promotes breast cancer chemoresistance. Cancer Chemother Pharmacol. 2021;87(2):147–58. https://doi.org/10.1007/s00280-020-04222-w.CrossRefPubMed

247.

Biswas, S., G. Mandal, S. Roy Chowdhury, et al.1, Exosomes produced by mesenchymal stem cells drive differentiation of myeloid cells into immunosuppressive M2-polarized macrophages in breast cancer. J Immunol, 2019. 203(12): p. 3447–3460. https://doi.org/10.4049/jimmunol.1900692.

248.

Chen HW, Chen HY, Wang LT, et al. 1, Mesenchymal stem cells tune the development of monocyte-derived dendritic cells toward a myeloid-derived suppressive phenotype through growth-regulated oncogene chemokines. J Immunol. 2013;190(10):5065–77. https://doi.org/10.4049/jimmunol.1202775.CrossRefPubMed

249.

Liubomirski Y, Lerrer S, Meshel T, et al. 1, Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer. Front Immunol. 2019;10:757. https://doi.org/10.3389/fimmu.2019.00757.CrossRefPubMedPubMedCentral

250.

Böcker W, Docheva D, Prall WC, et al. 1, IKK-2 is required for TNF-alpha-induced invasion and proliferation of human mesenchymal stem cells. J Mol Med (Berl). 2008;86(10):1183–92. https://doi.org/10.1007/s00109-008-0378-3.CrossRefPubMed

251.

Beldi G, Khosravi M, Abdelgawad ME, et al. 1, TNFα/TNFR2 signaling pathway: an active immune checkpoint for mesenchymal stem cell immunoregulatory function. Stem Cell Res Ther. 2020;11(1):281. https://doi.org/10.1186/s13287-020-01740-5.CrossRefPubMedPubMedCentral

252.

Beldi G, Bahiraii S, Lezin C, et al. 1, TNFR2 Is a Crucial Hub Controlling Mesenchymal Stem Cell Biological and Functional Properties. Front Cell Dev Biol. 2020;8: 596831. https://doi.org/10.3389/fcell.2020.596831.CrossRefPubMedPubMedCentral

253.

Naserian S, Shamdani S, Arouche N, et al. 1, Regulatory T cell induction by mesenchymal stem cells depends on the expression of TNFR2 by T cells. Stem Cell Res Ther. 2020;11(1):534. https://doi.org/10.1186/s13287-020-02057-z.CrossRefPubMedPubMedCentral

254.

Shi Y, Du L, Lin L, et al. 1, Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. Nat Rev Drug Discov. 2017;16(1):35–52. https://doi.org/10.1038/nrd.2016.193.CrossRefPubMed

255.

Wang Y, Wang M, Abarbanell AM, et al. 1, MEK mediates the novel cross talk between TNFR2 and TGF-EGFR in enhancing vascular endothelial growth factor (VEGF) secretion from human mesenchymal stem cells. Surgery. 2009;146(2):198–205. https://doi.org/10.1016/j.surg.2009.04.013.CrossRefPubMed

256.

Wang Y, Weil BR, Herrmann JL, et al. 1, MEK, p38, and PI-3K mediate cross talk between EGFR and TNFR in enhancing hepatocyte growth factor production from human mesenchymal stem cells. Am J Physiol Cell Physiol. 2009;297(5):C1284–93. https://doi.org/10.1152/ajpcell.00183.2009.CrossRefPubMedPubMedCentral

257.

Naserian, S., M.E. Abdelgawad, M. Afshar Bakshloo, et al.1, The TNF/TNFR2 signaling pathway is a key regulatory factor in endothelial progenitor cell immunosuppressive effect. Cell Commun Signal 2020. 18(1): p. 94. https://doi.org/10.1186/s12964-020-00564-3.

258.

George AL, Rajoria S, Suriano R, et al. 1, Hypoxia and estrogen are functionally equivalent in breast cancer-endothelial cell interdependence. Mol Cancer. 2012;11(1):80. https://doi.org/10.1186/1476-4598-11-80.CrossRefPubMedPubMedCentral

259.

Orimo A, Gupta PB, Sgroi DC, et al. 1, Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion. Cell. 2005;121(3):335–48. https://doi.org/10.1016/j.cell.2005.02.034.CrossRefPubMed

260.

Prisco AR, Hoffmann BR, Kaczorowski CC, et al. 1, Tumor Necrosis Factor α Regulates Endothelial Progenitor Cell Migration via CADM1 and NF-kB. Stem Cells. 2016;34(7):1922–33. https://doi.org/10.1002/stem.2339.CrossRefPubMed

261.

Nouri Barkestani, M., S. Shamdani, M. Afshar Bakshloo, et al.1, TNFα priming through its interaction with TNFR2 enhances endothelial progenitor cell immunosuppressive effect: new hope for their widespread clinical application. Cell Commun Signal, 2021. 19(1): p. 1. https://doi.org/10.1186/s12964-020-00683-x.

262.

Hu D, Li Z, Zheng B, et al. 1, Cancer-associated fibroblasts in breast cancer: Challenges and opportunities. Cancer Commun. 2022;42(5):401–34. https://doi.org/10.1002/cac2.12291.CrossRef

263.

Chen, X. and E. Song1, Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov 2019. 18(2): p. 99–115. https://doi.org/10.1038/s41573-018-0004-1.

264.

Fang Z, Meng Q, Xu J, et al. 1, Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives. Cancer Commun. 2023;43(1):3–41. https://doi.org/10.1002/cac2.12392.CrossRef

265.

Zhang J, Shi Z, Xu X, et al. 1, The influence of microenvironment on tumor immunotherapy. FEBS J. 2019;286(21):4160–75. https://doi.org/10.1111/febs.15028.CrossRefPubMedPubMedCentral

266.

Huang M, Li Y, Zhang H, et al. 1, Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction. J Exp Clin Cancer Res. 2010;29(1):80. https://doi.org/10.1186/1756-9966-29-80.CrossRefPubMedPubMedCentral

267.

Zhou Q, Wu X, Wang X, et al. 1, The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-α/IL-33/ST2L signaling promotes gastric cancer metastasis. Oncogene. 2020;39(7):1414–28. https://doi.org/10.1038/s41388-019-1078-x.CrossRefPubMed

268.

Jiang W, Lian J, Yue Y, et al. 1, IL-33/ST2 as a potential target for tumor immunotherapy. Eur J Immunol. 2021;51(8):1943–55. https://doi.org/10.1002/eji.202149175.CrossRefPubMed

269.

Fang W, Zhou T, Shi H, et al. 1, Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion. J Exp Clin Cancer Res. 2021;40(1):4. https://doi.org/10.1186/s13046-020-01786-6.CrossRefPubMedPubMedCentral

270.

Feig C, Jones JO, Kraman M, et al. 1, Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci. 2013;110(50):20212–7. https://doi.org/10.1073/pnas.1320318110.CrossRefPubMedPubMedCentral

271.

DeNardo, D.G. and B. Ruffell1, Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol, 2019. 19(6): p. 369–382. https://doi.org/10.1038/s41577-019-0127-6.

272.

Yang, J. and Y. Teng1, Harnessing cancer stem cell-derived exosomes to improve cancer therapy. J Exp Clin Cancer Res 2023. 42(1): p. 131. https://doi.org/10.1186/s13046-023-02717-x.

273.

Becker LM, O’Connell JT, Vo AP, et al. 1, Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer. Cell Rep. 2020;31(9): 107701. https://doi.org/10.1016/j.celrep.2020.107701.CrossRefPubMedPubMedCentral

274.

Wang L, Yang D, Tian J, et al. 1, Tumor necrosis factor receptor 2/AKT and ERK signaling pathways contribute to the switch from fibroblasts to CAFs by progranulin in microenvironment of colorectal cancer. Oncotarget. 2017;8(16):26323–33. https://doi.org/10.18632/oncotarget.15461.CrossRefPubMedPubMedCentral

275.

Michea P, Noël F, Zakine E, et al. 1, Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. Nat Immunol. 2018;19(8):885–97. https://doi.org/10.1038/s41590-018-0145-8.CrossRefPubMed

276.

Del Prete A, Salvi V, Soriani A, et al. 1, Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20(5):432–47. https://doi.org/10.1038/s41423-023-00990-6.CrossRefPubMedPubMedCentral

277.

Park MD, Belabed M, Chen ST, et al. 1, On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer. Annual Review of Cancer Biology. 2023;7(1):291–311. https://doi.org/10.1146/annurev-cancerbio-061521-085949.CrossRef

278.

Moussion, C. and I. Mellman1, The dendritic cell strikes back. Immunity, 2018. 49(6): p. 997–999. https://doi.org/10.1016/j.immuni.2018.12.007.

279.

Böttcher, J.P. and C. Reis e Sousa1, The role of type 1 conventional dendritic cells in cancer immunity. Trends in Cancer, 2018. 4(11): p. 784–792. https://doi.org/10.1016/j.trecan.2018.09.001.

280.

Meyer MA, Baer JM, Knolhoff BL, et al. 1, Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance. Nat Commun. 2018;9(1):1250. https://doi.org/10.1038/s41467-018-03600-6.CrossRefPubMedPubMedCentral

281.

Greenhough A, Smartt HJM, Moore AE, et al. 1, The COX-2/PGE 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009;30(3):377–86. https://doi.org/10.1093/carcin/bgp014.CrossRefPubMed

282.

Moreno Ayala, M.A., T.F. Campbell, C. Zhang, et al.1, CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8+ T cell antitumor immunity. Immunity, 2023. 56(7): p. 1613–1630.e5. https://doi.org/10.1016/j.immuni.2023.06.003.

283.

Tesarová P, Kvasnicka J, Umlaufová A, et al. 1, Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit. 2000;6(4):661–7.PubMed

284.

Bower JE, Ganz PA, Irwin MR, et al. 1, Inflammation and Behavioral Symptoms After Breast Cancer Treatment: Do Fatigue, Depression, and Sleep Disturbance Share a Common Underlying Mechanism? J Clin Oncol. 2011;29(26):3517–22. https://doi.org/10.1200/JCO.2011.36.1154.CrossRefPubMedPubMedCentral

285.

Smith AK, Conneely KN, Pace TW, et al. 1, Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav Immun. 2014;38:227–36. https://doi.org/10.1016/j.bbi.2014.02.010.CrossRefPubMedPubMedCentral

286.

Torres MA, Pace TW, Liu T, et al. 1, Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer. 2013;119(11):1951–9. https://doi.org/10.1002/cncr.28003.CrossRefPubMed

287.

Bower JE, Wiley J, Petersen L, et al. 1, Fatigue after breast cancer treatment: Biobehavioral predictors of fatigue trajectories. Health Psychol. 2018;37(11):1025–34. https://doi.org/10.1037/hea0000652.CrossRefPubMedPubMedCentral

288.

Gross AL, Newschaffer CJ, Hoffman-Bolton J, et al. 1, Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013;22(7):1319–24. https://doi.org/10.1158/1055-9965.Epi-12-1444.CrossRefPubMedPubMedCentral

289.

Williams AM, Shah R, Shayne M, et al. 1, Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy. J Neuroimmunol. 2018;314:17–23. https://doi.org/10.1016/j.jneuroim.2017.10.005.CrossRefPubMed

290.

Patel, S.K., A.L. Wong, F.L. Wong, et al.1, Inflammatory biomarkers, comorbidity, and neurocognition in women with newly diagnosed breast cancer. JNCI: J Natl Cancer Inst 2015. 107(8): p. djv131. https://doi.org/10.1093/jnci/djv131.

291.

Janelsins MC, Lei L, Netherby-Winslow C, et al. 1, Relationships between cytokines and cognitive function from pre- to post-chemotherapy in patients with breast cancer. J Neuroimmunol. 2022;362: 577769. https://doi.org/10.1016/j.jneuroim.2021.577769.CrossRefPubMed

292.

Bulska-Będkowska, W., P. Czajka-Francuz, S. Jurek-Cisoń, et al.1, The predictive role of serum levels of Soluble Cell Adhesion Molecules (sCAMs) in the therapy of advanced breast cancer-a single-centre study. Medicina (Kaunas), 2022. 58(2): p. https://doi.org/10.3390/medicina58020153.

293.

Hayslip J, Dressler EV, Weiss H, et al. 1, Plasma TNF-α and Soluble TNF Receptor Levels after Doxorubicin with or without Co-Administration of Mesna—A Randomized, Cross-Over Clinical Study. PLoS ONE. 2015;10(4): e0124988. https://doi.org/10.1371/journal.pone.0124988.CrossRefPubMedPubMedCentral

294.

Orchard TS, Andridge RR, Yee LD, et al. 1, Diet Quality, Inflammation, and Quality of Life in Breast Cancer Survivors: A Cross-Sectional Analysis of Pilot Study Data. J Acad Nutr Diet. 2018;118(4):578–588.e1. https://doi.org/10.1016/j.jand.2017.09.024.CrossRefPubMed

295.

Connor AE, Dibble KE, Boone SD, et al. 1, Systemic inflammation and risk of all-cause mortality after invasive breast cancer diagnosis among Hispanic and non-Hispanic white women from New Mexico. Cancer Epidemiol. 2022;76: 102092. https://doi.org/10.1016/j.canep.2021.102092.CrossRefPubMedPubMedCentral

296.

Krajcik, R.A., S. Massardo, and N. Orentreich1, No association between serum levels of tumor necrosis factor-alpha (TNF-alpha) or the soluble receptors sTNFR1 and sTNFR2 and breast cancer risk. Cancer Epidemiol Biomarkers Prev, 2003. 12(9): p. 945–6.

297.

Mestiri, S., N. Bouaouina, S. Ben Ahmed, et al.1, A functional polymorphism of the tumor necrosis factor receptor-II gene associated with the survival and relapse prediction of breast carcinoma. Cytokine, 2005. 30(4): p. 182–187. https://doi.org/10.1016/j.cyto.2005.01.007.

298.

Yang, F., Z. Zhao, and N. Zhao1, Clinical implications of tumor necrosis factor receptor 2 in breast cancer. Oncol Lett, 2017. 14(2): p. 2393–2398. https://doi.org/10.3892/ol.2017.6410.

299.

Baram, T., N. Erlichman, M. Dadiani, et al.1, Chemotherapy Shifts the Balance in Favor of CD8+ TNFR2+ TILs in Triple-Negative Breast Tumors. Cells, 2021. 10(6): p. https://doi.org/10.3390/cells10061429.

300.

Lerebours F, Vacher S, Andrieu C, et al. 1, NF-kappa B genes have a major role in Inflammatory Breast Cancer. BMC Cancer. 2008;8(1):41. https://doi.org/10.1186/1471-2407-8-41.CrossRefPubMedPubMedCentral

301.

Sarkar DK, Jana D, Patil PS, et al. 1, Role of NF-κB as a Prognostic Marker in Breast Cancer : A Pilot Study in Indian Patients. Indian J Surg Oncol. 2013;4(3):242–7. https://doi.org/10.1007/s13193-013-0234-y.CrossRefPubMedPubMedCentral

302.

García-Tuñón I, Ricote M, Ruiz A, et al. 1, Role of tumor necrosis factor-α and its receptors in human benign breast lesions and tumors (in situ and infiltrative). Cancer Sci. 2006;97(10):1044–9. https://doi.org/10.1111/j.1349-7006.2006.00277.x.CrossRefPubMedPubMedCentral

303.

Cui LF, Guo XJ, Wei J, et al. 1, Overexpression of TNF-alpha and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations. Histopathology. 2008;53(4):381–8. https://doi.org/10.1111/j.1365-2559.2008.03128.x.CrossRefPubMed

304.

Case K, Tran L, Yang M, et al. 1, TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models. J Leukoc Biol. 2020;107(6):981–91. https://doi.org/10.1002/jlb.5ma0420-375rrrrr.CrossRefPubMed

305.

Torrey, H., J. Butterworth, T. Mera, et al.1, Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Science Signaling, 2017. 10(462): p. eaaf8608. https://doi.org/10.1126/scisignal.aaf8608.

306.

Jiang M, Liu J, Yang D, et al. 1, A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer. Int Immunopharmacol. 2021;101: 108345. https://doi.org/10.1016/j.intimp.2021.108345.CrossRefPubMedPubMedCentral

307.

Zhu L, Zhang X, Chen X, et al. 1, Anti-TNFR2 enhanced the antitumor activity of a new HMGN1/3M-052 stimulated dendritic cell vaccine in a mouse model of colon cancer. Biochem Biophys Res Commun. 2023;653:106–14. https://doi.org/10.1016/j.bbrc.2023.02.039.CrossRefPubMed

308.

Chen S, Li R, Chen Y, et al. 1, Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4+Foxp3+ regulatory T cells. Biomed Pharmacother. 2022;151: 113187. https://doi.org/10.1016/j.biopha.2022.113187.CrossRefPubMed

309.

van der Most RG, Currie AJ, Mahendran S, et al. 1, Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother. 2009;58(8):1219–28. https://doi.org/10.1007/s00262-008-0628-9.CrossRefPubMed

310.

Torrey H, Butterworth J, Mera T, et al. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal. 2017;10(462):eaaf8608. https://doi.org/10.1126/scisignal.aaf8608.

311.

Torrey, H., J. Butterworth, T. Mera, et al.1, Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal, 2017. 10(462): p. https://doi.org/10.1126/scisignal.aaf8608.

312.

He T, Liu S, Chen S, et al. 1, The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4(+)Foxp3(+) Regulatory T Cells. Front Immunol. 2018;9:1556. https://doi.org/10.3389/fimmu.2018.01556.CrossRefPubMedPubMedCentral

313.

Tam, E.M., R.B. Fulton, J.F. Sampson, et al.1, Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity. Sci Transl Med 2019. 11(512): p. eaax0720. https://doi.org/10.1126/scitranslmed.aax0720.

314.

Yang M, Tran L, Torrey H, et al. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity. J Leukoc Biol. 2020;107(6):971–80. https://doi.org/10.1002/jlb.5ab0320-415rrrrr.CrossRefPubMed

315.

Chen Y, Jia M, Wang S, et al. 1, Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity. Front Immunol. 2022;13: 835690. https://doi.org/10.3389/fimmu.2022.835690.CrossRefPubMedPubMedCentral

316.

Ma J, Mo Y, Tang M, et al. 1, Bispecific Antibodies: From Research to Clinical Application. Front Immunol. 2021;12: 626616. https://doi.org/10.3389/fimmu.2021.626616.CrossRefPubMedPubMedCentral

317.

Labrijn AF, Janmaat ML, Reichert JM, et al. 1, Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discovery. 2019;18(8):585–608. https://doi.org/10.1038/s41573-019-0028-1.CrossRefPubMed

318.

Klein C, Brinkmann U, Reichert JM, et al. 1, The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discovery. 2024. https://doi.org/10.1038/s41573-024-00896-6.CrossRefPubMed

319.

Lim SM, Pyo K-H, Soo RA, et al. 1, The promise of bispecific antibodies: Clinical applications and challenges. Cancer Treat Rev. 2021;99: 102240. https://doi.org/10.1016/j.ctrv.2021.102240.CrossRefPubMed

320.

Larbouret, C., B. Robert, C. Linard, et al.1, Radiocurability by targeting tumor necrosis factor-α using a bispecific antibody in carcinoembryonic antigen transgenic mice. Int J Radiat Oncol*Biol*Phys, 2007. 69(4): p. 1231–1237. https://doi.org/10.1016/j.ijrobp.2007.07.2372.

321.

Jung K, Lee D, Lim HS, et al. 1, Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem. 2011;286(16):14410–8. https://doi.org/10.1074/jbc.M111.228130.CrossRefPubMedPubMedCentral

322.

Zhang N, Zheng N, Luo D, et al. 1, A novel single domain bispecific antibody targeting VEGF and TNF-α ameliorates rheumatoid arthritis. Int Immunopharmacol. 2024;126: 111240. https://doi.org/10.1016/j.intimp.2023.111240.CrossRefPubMed

323.

Kanakaraj P, Puffer BA, Yao XT, et al. 1, Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis. MAbs. 2012;4(5):600–13. https://doi.org/10.4161/mabs.21227.CrossRefPubMedPubMedCentral

324.

Fischer JAA, Hueber AJ, Wilson S, et al. 1, Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis: Development and Characterization of a Novel Bispecific Antibody. Arthritis & Rheumatology. 2015;67(1):51–62. https://doi.org/10.1002/art.38896.CrossRef

325.

Xu T, Ying T, Wang L, et al. 1, A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A. Oncotarget. 2017;8(47):81860–72. https://doi.org/10.18632/oncotarget.19899.CrossRefPubMedPubMedCentral

326.

Zheng, S., F. Shen, B. Jones, et al.1, Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A. mAbs, 2020. 12(1): p. 1770018. https://doi.org/10.1080/19420862.2020.1770018.

327.

Biesemann, N., D. Margerie, C. Asbrand, et al.1, Additive efficacy of a bispecific anti–TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis. Science Translational Medicine. 15(681): p. eabq4419. https://doi.org/10.1126/scitranslmed.abq4419.

328.

Li A, Xing J, Li L, et al. 1, A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells. AMB Express. 2016;6(1):32. https://doi.org/10.1186/s13568-016-0201-4.CrossRefPubMedPubMedCentral

329.

Schmohl JU, Felices M, Taras E, et al. 1, Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker. Mol Ther. 2016;24(7):1312–22. https://doi.org/10.1038/mt.2016.88.CrossRefPubMedPubMedCentral

330.

von Strandmann EP, Hansen HP, Reiners KS, et al. 1, A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood. 2006;107(5):1955–62. https://doi.org/10.1182/blood-2005-05-2177.CrossRef

331.

Li Y, Zhou C, Li J, et al. 1, Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. PLoS ONE. 2018;13(1): e0191024. https://doi.org/10.1371/journal.pone.0191024.CrossRefPubMedPubMedCentral

332.

Jackson, H.J., S. Rafiq, and R.J. Brentjens1, Driving CAR T-cells forward. Nature Reviews Clinical Oncology, 2016. 13(6): p. 370–383. https://doi.org/10.1038/nrclinonc.2016.36.

333.

Song, E.Z. and M.C. Milone1, Pharmacology of Chimeric Antigen Receptor-Modified T Cells. Annu Rev Pharmacol Toxicol, 2021. 61: p. 805–829. https://doi.org/10.1146/annurev-pharmtox-031720-102211.

334.

Schmidts, A., M. Wehrli, and M.V. Maus1, Toward Better Understanding and Management of CAR-T Cell-Associated Toxicity. Annu Rev Med, 2021. 72: p. 365–382. https://doi.org/10.1146/annurev-med-061119-015600.

335.

Albelda, S.M.1, CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nature Reviews Clinical Oncology, 2024. 21(1): p. 47–66. https://doi.org/10.1038/s41571-023-00832-4.

336.

Sadelain, M.1, Chimeric antigen receptors: driving immunology towards synthetic biology. Curr Opin Immunol, 2016. 41: p. 68–76. https://doi.org/10.1016/j.coi.2016.06.004.

337.

Sadelain, M.1, Chimeric antigen receptors: a paradigm shift in immunotherapy. annual review of cancer biology, 2017. 1(Volume 1, 2017): p. 447–466. https://doi.org/10.1146/annurev-cancerbio-050216-034351.

338.

Jung M, Yang Y, McCloskey JE, et al. Chimeric antigen receptor T cell therapy targeting ICAM-1 in gastric cancer. Mol Ther - Oncolytics. 2020;18:587–601. https://doi.org/10.1016/j.omto.2020.08.009.CrossRefPubMedPubMedCentral

339.

Ba, H., Z. Dai, Z. Zhang, et al.1, Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers. J Immunother Cancer, 2023. 11(1): p. https://doi.org/10.1136/jitc-2021-003837.

340.

Sun R, Sun Y, Wu C, et al. 1, CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer. Mol Ther. 2023;31(11):3193–209. https://doi.org/10.1016/j.ymthe.2023.09.010.CrossRefPubMedPubMedCentral

341.

Manriquez Roman, C., M.J. Cox, R. Sakemura, et al.1, TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma. Blood, 2021. 138(Supplement 1): p. 901–901. https://doi.org/10.1182/blood-2021-148591.

342.

Hou, A.J., L.C. Chen, and Y.Y. Chen1, Navigating CAR-T cells through the solid-tumour microenvironment. Nature Reviews Drug Discovery, 2021. 20(7): p. 531–550. https://doi.org/10.1038/s41573-021-00189-2.

343.

Gao, T.A. and Y.Y. Chen1, Engineering next-generation CAR-T cells: overcoming tumor hypoxia and metabolism. Annual Rev Chem Biomol Eng 2022. 13(Volume 13, 2022): p. 193–216. https://doi.org/10.1146/annurev-chembioeng-092120-092914.

344.

Xie G, Dong H, Liang Y, et al. 1, CAR-NK cells: A promising cellular immunotherapy for cancer. EBioMedicine. 2020;59: 102975. https://doi.org/10.1016/j.ebiom.2020.102975.CrossRefPubMedPubMedCentral

Keynote series | Spotlight on menopause

Springer Medicine

Understanding the role of TNFR2 signaling in the tumor microenvironment of breast cancer

Abstract

Other articles of this Issue 1/2024

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy

METTL14 suppresses the expression of YAP1 and the stemness of triple-negative breast cancer

Tumor-derived GLI1 promotes remodeling of the immune tumor microenvironment in melanoma

MAGOH promotes gastric cancer progression via hnRNPA1 expression inhibition-mediated RONΔ160/PI3K/AKT signaling pathway activation

Circulating tumour DNA dynamics predict recurrence in stage III melanoma patients receiving neoadjuvant immunotherapy

CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote series | Spotlight on menopause

Springer Medicine

Abstract

Please log in to get access to this content

ASH 2024 Annual Meeting Coverage